← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	2,256	+52	+2%	$185B
2	2 Amgen AMGN $238B	1,796	+33	+2%	$104B
3	3 Eli Lilly LLY $1.13T	1,431	+63	+5%	$88.7B
4	4 Becton Dickinson BDX $52.5B	1,316	+31	+2%	$59.6B
5	5 McKesson MCK $116B	851	-53	-6%	$22.5B
6	6 Conagra Brands CAG $6.83B	713	-30	-4%	$11.8B
7	7 Regeneron Pharmaceuticals REGN $82.4B	644	+20	+3%	$29.8B
8	8 Novo Nordisk NVO $174B	557	+21	+4%	$7.89B
9	9 Teva Pharmaceutical Industries Limited TEVA $48.2B	556	+17	+3%	$13.7B
10	10 AstraZeneca AZN $260B	545	+14	+3%	$17.4B
11	11 Lamb Weston LW $7.47B	544	-3	-0.5%	$7.88B
12	12 ResMed RMD $33.9B	497	+32	+7%	$10.9B
13	13 DaVita DVA $11.9B	490	+11	+2%	$10.5B
14	14 West Pharmaceutical WST $26.9B	354	+31	+10%	$8.52B
15	15 DELISTED WW International WW	297	+36	+14%	$4.47B
16	16 DELISTED CATALENT, INC. CTLT	277	+15	+6%	$6.49B
17	17 Medifast MED $135M	266	+8	+3%	$2.42B
18	18 Herbalife HLF $1.52B	261	+38	+17%	$7.71B
19	19 Fresenius Medical Care FMS $11.8B	222	-3	-1%	$772M
20	20 Accendra Health ACH $20.9M	219	-10	-4%	$928M
21	21 Opko Health OPK $1.16B	203	-11	-5%	$526M
22	22 Tootsie Roll Industries TR $2.9B	172	-1	-0.6%	$411M
23	ARNA 23 DELISTED Arena Pharmaceuticals Inc ARNA	160	-5	-3%	$1.85B
24	24 Madrigal Pharmaceuticals MDGL $10.7B	156	+8	+5%	$1.85B
25	25 Viking Therapeutics VKTX $3.45B	148	+32	+28%	$753M